Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
Nutrient competition provides a predictive framework to anticipate and potentially mitigate drug side effects on the gut microbiota.
The interaction between gut microbes, the amino acid leucine and sIL-6R determines a person’s responsiveness to exercise.
Future studies should have clearly defined hypotheses, adequate sample size, standardized protocols, and replication using multiple independent approaches.
Changes in gut bacteria raise a child’s chances of developing IBD later in life, offering clues to why the conditions sometimes runs in families.
Certain harmful microbes in the mouth appear to promote cancer development, while others might help protect against it.
Researchers set up a clinical trial to study how glucocorticoids affected the gut microbiota, metabolism, and immunity in healthy young men.
Gut bacteria help protect the liver by breaking down sorbitol, a sugar made from glucose in the gut.
The researchers created a microbial catalog, which they called HROM (human reference oral microbiome), containing 72,641 high-quality genomes from 3,426 species.
Diet and gut microbes can shape immune cell function and improve responses to anti-cancer therapy.
A gut bacterium, Clostridium steroidoreducens, can chemically modify steroid hormones, including those used to treat IBD.
